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Background-—Stroke is among the leading causes of morbidity and mortality worldwide. Without reliable prediction models and
outcome measurements, comparison of care systems is impossible. We analyzed prospectively collected data from 4 countries to
explore the importance of stroke severity in outcome prediction.
Methods and Results-—For 2 months, all acute ischemic stroke patients from the hospitals participating in the Global
Comparators Stroke GOAL (Global Outcomes Accelerated Learning) collaboration received a National Institutes of Health Stroke
Scale (NIHSS) score on admission and a modiﬁed Rankin Scale score at 30 and 90 days. These data were added to the
administrative data set, and risk prediction models including age, sex, comorbidity index, and NIHSS were derived for in-hospital
death within 7 days, all in-hospital death, and death and good outcome at 30 and 90 days. The relative importance of each variable
was assessed using the proportion of explained variation. Of 1034 admissions for acute ischemic stroke, 614 had a full set of
NIHSS and both modiﬁed Rankin Scale values recorded; of these, 507 patients could be linked to administrative data. The marginal
proportion of explained variation was 0.7% to 4.0% for comorbidity index, and 11.3 to 25.0 for NIHSS score. The percentage
explained by the model varied by outcome (16.6–29.1%) and was highest for good outcome at 30 and 90 days. There was high
agreement between 30- and 90-day modiﬁed Rankin Scale scores (weighted j=0.82).
Conclusions-—In this prospective pilot study, the baseline NIHSS score was essential for prediction of acute ischemic stroke
outcomes, followed by age; whereas traditional comorbidity index contributed little to the overall model. Future studies of stroke
outcomes between different care systems will beneﬁt from including a baseline NIHSS score. ( J Am Heart Assoc. 2016;5:
e002433 doi: 10.1161/JAHA.115.002433)
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S troke is the second leading cause of death worldwide anda leading cause of adult disability.1 Despite currently
available treatment options for stroke, patients often face the
prospect of signiﬁcant poststroke disability.2 The implemen-
tation of regional and nationwide stroke systems of care and
quality-improvement initiatives has signiﬁcant impact on
reducing stroke-related morbidity and improving out-
comes.3–6
The Global Comparators Stroke GOAL collaboration is an
international project facilitated by Dr Foster (www.drfoster.
com) with participation from >40 hospitals in Europe, the
United States, and Australia.7 The participating hospitals are a
selected group of mostly academic hospitals that have been
collaborating to share data and compare clinical outcomes
and performance across international boundaries. The overall
aim of the Global Comparators Stroke GOAL program is to
compare stroke systems of care and outcomes across regions
and countries.
The modiﬁed Rankin Scale (mRS) is a validated measure of
functional outcome after stroke (ranging from 0, indicating no
symptoms at all, to 6, indicating death), commonly used in
large-scale multicenter stroke trials and prospective studies
of poststroke disability.8–10 The utility of the mRS has been
tested in modiﬁed telephone-based interviews11,12 and at
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different time points after stroke.13,14 A number of prior
poststroke outcome studies have used mRS in their prediction
models, including the multinational Virtual International
Stroke Trials Archives (VISTA); however, the majority of
reports were based on the retrospective analysis of historical
data.15,16 A major motivation for the current study was to
design and implement a prospective international pilot project
to validate the mRS as a robust stroke outcome measure and
the National Institutes of Health Stroke Scale (NIHSS) score
as a reliable predictor of outcome for future use in multina-
tional database research.
Methods
Dr Foster and Global Comparators’ Stroke GOAL
Initiative
As part of the Global Comparators collaboration facilitated by
health care information company Dr Foster,7 the Stroke GOAL
program included 13 hospitals from the United States, the
United Kingdom, and Europe that contributed prospective
data for this analysis at the time of this pilot project in 2012
(participating hospitals are listed in the Acknowledgements).
Data Collection and Variable Deﬁnitions
The following variables were available in the administrative
database: age, sex, comorbidity index (CMI), and NIHSS score
as well as in-hospital death within 7 days, all in-hospital
death, 30- and 90-day death, and mRS at 30 and 90 days.
CMI had been derived previously with weights speciﬁc to
stroke and in-hospital death, using all records in the Global
Comparators project, with 31 comorbidities taken from the
Elixhauser index, plus dementia.7
Prospective Stroke-Speciﬁc Characteristics
The mRS is a reliable and valid functional poststroke outcome
assessment scale; furthermore, the mRS is useful for
measurement of 30- to 90-day patient outcome, is available
in all languages used throughout the Global Comparators
network, and can be performed using structured interviews.
An mRS performed at 30 days after stroke may prove to be
more feasible as a systematic measurement while serving as a
reliable proxy for ﬁnal outcome.17 Because most research
studies that validated the mRS after stroke allowed comple-
tion of the examination until 100 days after stroke, we
included this expanded time window for follow-up. It is
uncertain whether 90-day mRS is superior to 30-day
measurement.
The NIHSS is a systematic assessment tool that provides a
quantitative measure of stroke-related neurological deﬁcit.18
The NIHSS was originally designed as a research tool to
measure baseline data from patients in acute stroke clinical
trials. The scale is widely used today as a clinical assessment
tool to evaluate severity of stroke, to determine appropriate
treatment, and to predict patient outcome.19
Inclusion and Exclusion Criteria
The target population consisted of adult patients with acute
ischemic stroke (AIS). To link the included patients to the
patients included in the Global Comparators Stroke GOAL
project, the following inclusion criteria were used: (1)
discharge primary diagnosis of AIS, (2) patient aged ≥18
years, and (3) admission to the hospital with ≥1 overnight
stay. Exclusion criteria included (1) discharge diagnosis of
transient ischemic attack (except if acute ischemic lesion was
present on diffusion weighted imaging), (2) discharge diagno-
sis of intracerebral hemorrhage, or (3) discharge diagnosis of
subarachnoid hemorrhage.
Pilot Implementation: Data Collection and Patient
Follow-up
All AIS patients admitted to the participating hospitals
between March 1, 2012, and April 30, 2012 were included
in this prospective pilot study. The patients were followed for
90 days after their admission for assessment of ﬁnal
poststroke outcome. With exception of the in-hospital stroke
cases, all AIS patients admitted to the stroke or neurology
department by stroke team staff or designees during the pilot
timeline were enrolled. All patients were assigned an NIHSS
score before intravenous tissue plasminogen activator admin-
istration or other acute reperfusion therapies or within
24 hours of admission.
For each patient or patient’s surrogate, reliable contact
information was obtained to assess outcome in person (eg,
clinic follow-up) or by telephone or telemedicine between 30
and 90 days from the incident stroke. The mRS score was
obtained at 30 days (+7 days allowed to establish contact)
and then at 90 days (+14 days allowed for conducting the
mRS). In patients who were still in the acute care facility at
day 90, an in-hospital mRS score was obtained. Patients who
were deceased before day 90 were included and received an
mRS score of 6. Patients who were lost to follow-up received
the last recorded mRS or an mRS derived from the last
documented neurological evaluation as their ﬁnal score. The
NIHSS score and the mRS scores between days 30 and 90
were transmitted to Dr Foster. The NIHSS and mRS informa-
tion was linked to the administrative database submitted by
each hospital for the larger Global Comparators project using
each hospital’s pseudoidentiﬁer and admission data, allowing
1 day either way.
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Waiver of Consent
All patients admitted to the hospital for diagnosis and
management of AIS were entered in the acute stroke quality
improvement database at our respective institutions. These
data were collected for quality improvement purposes and
were deidentiﬁed for the purpose of this project. Furthermore,
only data available in the medical record were available for
abstraction; therefore, each respective institutional review
board either had already waived the need for informed
consent and approved such type of database analysis or
expedited this waiver prior to project commencement on April
1, 2012.
Statistical Analysis
Medians and interquartile ranges (IQRs) for NIHSS scores
were derived for the country groups of hospitals and
compared using a 2-sample comparison of medians test.
Outcomes were tabulated by center. Because the mRS is
ordinal, the association between 30- and 90-day mRS scores
was assessed using the c statistic and polychoric correlation
coefﬁcients. To evaluate whether the effect of patient
characteristics on outcome varied by length of follow-up or
type of outcome, logistic regression models were ﬁtted for
each outcome with NIHSS (continuous or as a category by
NIHSS score: mild, 0–6; moderate, 7–16; severe, 17–40). This
was done for all records with complete NIHSS and mRS data.
The earliest outcome time point considered in the analyses
was 7 days. We repeated the regression in the subset that
could be linked to the administrative data and included age
(continuous), sex, and CMI (continuous).
The performance of the regression models was summa-
rized using the c-statistic and the Hosmer-Lemeshow
statistic. The c-statistic assesses the model’s discrimina-
tion—its ability to predict a higher risk of death for patients
who died than for patients who lived—and values >0.8 are
often considered to represent good discrimination. The
Hosmer-Lemeshow statistic assesses the model’s calibra-
tion, or how accurate the predicted risks are when patients
are divided into groups of 10; by convention, P>0.05
suggests good discrimination.
The marginal proportion of explained variation was
estimated for each variable and outcome with the matched
data. This is the contribution of each variable to the variation
explained by the model when the variable is considered by
itself (ie, without any other variables included). We used
bootstrapping to enable signiﬁcance testing for comparison of
proportion of explained variation between predictors. All
analyses were run using SAS version 9.2 (SAS Institute). A
SAS macro for the proportion of explained variation was
obtained from the Internet.20
Results
There were 1034 admissions for AIS captured during the
project period. Of these, 614 records (59%) in 13 hospitals
had valid NIHSS and 30- and 90-day mRS scores recorded;
furthermore, 507 of 614 (82.6%) could be linked to the
administrative records to obtain CMI, length of stay, and in-
hospital death status. Table 1 summarizes the total number of
AIS patients admitted over the duration of the pilot study by
each participating hospital, with outcomes among the sample.
Table 2 demonstrates distribution of mRS scores at 30 and
90 days. Comparison of demographic data and comorbidities
for the patients with and without missing NIHSS and mRS
values showed no signiﬁcant differences except for those
patients with missing NIHSS data, who were, on average,
3.7 years younger than those with no missing NIHSS data
(P=0.02).
Stroke severity was similar between the country groups of
hospitals included in this analysis (median NIHSS score:
United Kingdom: 5 [IQR 2–13], n=180; United States: 5 [IQR
2–13], n=257; other countries: 5 [IQR 2–13], n=177; 2-
sample comparison of medians P=0.11). The counts of in-
hospital deaths within 7 days were low (by country group:
n=10, United Kingdom; n=18, United States; n=2, other
countries).
The 30- and 90-day mRS scores showed very high
correlation (q statistics were at least +0.90, for which 1.0
equals perfect association), both overall and when stratiﬁed
by severity (using mild, moderate, and severe categories).
Correlation was highest (q=0.97) for severe strokes. Results
were unchanged if death was excluded. Furthermore, there
was high agreement between 30- and 90-day mRS scores
(weighted j=0.82).21
NIHSS score dominated the models for all outcomes,
particularly for 7-day in-hospital death. Table 3 provides the
Hosmer-Lemeshow and c-statistics and whether each covari-
ate was signiﬁcant at P<0.05 for each outcome.22
Calibration was good in each case (Hosmer-Lemeshow
P>0.05), although less so for mRS scores <2. Discrimination
was highest for 7-day deaths. Fitting severity as a category
resulted in the loss of an appreciable amount of information
compared with including it as raw scores.
The results for proportion of explained variation agreed
with the P values from the regression (Table 4). They
demonstrate that NIHSS score dominates the variation in all
outcomes explained by the model, with age as the second
most important of the 4 variables. NIHSS score was
signiﬁcantly more important than comorbidity for all out-
comes (P<0.001 for all comparisons) and was more important
than the 3 other covariates for all outcomes (P<0.01 for all
comparisons). CMI had the greatest proportion of explained
variation for 90-day death. Some of CMI’s marginal effect is
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explained by the other variables when they are added to the
model. Overall, age, sex, NIHSS score, and CMI explain up to
about a quarter of the variation in the outcome but less for 7-
day in-hospital death.
Discussion
Results from this prospective multinational hospital-based
collaboration demonstrated (1) that 30-day mRS score is a
valid proxy for long-term functional outcome (90-day mRS
score) after ischemic stroke, (2) that stroke severity is an
essential predictor of poststroke outcomes in comparisons of
regional and national stroke systems of care, and (3) that
additional predictors are required to explain the remaining
variability in stroke outcomes.
The Stroke GOAL program initially analyzed administrative
data from all collaborating hospitals. These data relied on
outcome measures that were limited to in-hospital mortality,
length of stay, and 30-day readmission. Due to signiﬁcant
differences in care systems, these outcomemeasures were not
reliable indicators for comparison of poststroke outcomes
across multinational samples. Length of stay, for example,
varies widely across countries and regions and affects in-
hospital mortality and 30-day readmission. In England, for
example, some rehabilitation is often done in the acute hospital,
leading to longer mean stays than in the United States. In
addition, differences in referral patterns make in-hospital
mortality unreliable because some centers transfer patients
more frequently to outside facilities than others. Because the
Global Comparators database includes records only for partic-
ipating hospitals, it cannot capture posttransfer activity.
We selected the mRS as an outcome measurement in this
multinational sample. It is widely available in all languages
throughout our network, and it is reliable and validated using
face-to-face interviews and telephone interviews.12,23–27
Since its ﬁrst report, the scale has become the most widely
accepted clinician-reported measure of global disability for
evaluating recovery from stroke28 and is often used as a
primary end point in randomized clinical trials of emerging
acute stroke treatments.10,28 Our data demonstrate that the
mRS is a valid measurement of poststroke outcome and that
measurement of mRS score at 90 days provides only a little
additional information above the mRS score at 30 days. This is
consistent with previously published study-speciﬁc data14,17
and indicates that 30-day mRS score could be used as a
Table 1. Per-Center Enrollment and Outcomes in the Stroke GOAL Pilot Project (n=614)
Patients (N) Country* NIHSS Score† Death7 (n) Death (n)
Death Using
mRS30 (n)
Death Using
mRS90 (n) mRS30<2 (n) mRS30≤2 (n) mRS90<2 (n) mRS90≤2 (n)
89 US 4 (2–7) 3 5 11 15 28 36 31 41
82 US 6 (3–14) 5 5 10 12 26 36 31 36
81 UK 9 (3–15) 8 16 18 20 23 24 22 26
74 US 4 (2–14) 10 13 16 24 25 34 27 33
61 Other 6 (2–14) 1 4 6 10 18 19 19 20
56 UK 2 (1–9.5) 1 2 2 2 32 37 35 40
40 Other 4 (2–9) 0 0 3 4 15 23 24 26
39 Other 5 (2–13) 1 1 5 6 6 16 6 18
35 Other 6 (1–14) 0 0 9 9 16 18 17 19
27 UK 6 (2–10) 0 2 1 2 14 15 14 17
16 UK 5 (2.5–18) 1 1 1 2 2 4 7 9
12 US 12.5 (6–19.5) 0 0 2 2 4 5 4 5
2 Other 20 (19–21) 0 0 1 1 0 0 0 0
Death indicates overall in-hospital mortality; death7, mortality within 7 days; mRS30, modiﬁed Rankin Scale score at 30 days; mRS90, modiﬁed Rankin Scale score at 90 days; NIHSS,
National Institutes of Health Stroke Scale score.
*Other includes Belgium, Italy, and Netherlands.†NIHSS score is expressed as median (interquartile range).
Table 2. Distribution of 30- and 90-Day Modiﬁed Rankin
Scale Scores (n=614)
mRS
30-Day
Count
% of 30-Day
Total
90-Day
Count
% of 90-Day
Total
0 95 15.4 129 21.0
1 114 18.5 108 17.6
2 58 9.4 53 8.6
3 85 13.8 83 13.5
4 99 16.1 83 13.5
5 78 12.7 49 8.0
6 85 13.8 109 17.7
mRS indicates modiﬁed Rankin Scale score.
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reliable proxy for a long-term functional outcome measure in
future studies of poststroke outcomes in large multinational
collaborations.
In this analysis, the numbers of in-hospital deaths were too
few over the course of 2-month enrollment to allow compar-
isons between hospitals. In contrast, analyzing good out-
comes seemed viable at 30 or 90 days using the mRS;
therefore, functional poststroke outcome assessment may
offer a more reliable measure of hospital-based stroke
outcomes10,28 versus in-hospital mortality when using multi-
ple data sets with considerable degrees of variability.
Including stroke severity measured as an NIHSS score into
stroke outcome models is becoming a standard statistical
approach in planning and implementation of randomized
clinical trials of stroke.29,30 Furthermore, a large-scale,
outcome-based study of AIS reafﬁrmed the importance of
adding a stroke severity measure such as NIHSS score to a
hospital 30-day model because it considerably improved
model discrimination and changed the mortality performance
hospital ranking,31 a major practical implication for setting the
standard in hospital quality data analysis. Our data further
support these advances in applied stroke outcome prediction
modeling by demonstrating that inclusion of NIHSS score into
statistical modeling uniformly affected prediction of out-
comes. Moreover, NIHSS score appears to be a far more
important predictor than comorbidity score (ie, CMI), previ-
ously thought to be an important contributor to outcomes.
Because previously used measures such as mortality, length
of stay, and readmission rate for stroke patients cannot be
adequately corrected for stroke severity, they have only
limited utility for comparison of stroke outcomes.19 This issue
has become central in developing properly risk-adjusted
outcome measures for stroke to ensure quality care.32 Our
ﬁndings ﬁrmly support this development and suggest that all
future comparisons of the hospital-level performance and
outcomes in stroke must include stroke severity measured by
the NIHSS as a critical predictor of functional outcomes.
Study Strengths and Limitations
The strengths of this analysis are (1) the prospective nature of
this international collaboration, (2) the prespeciﬁed data
collection and statistical analysis plan, (3) the inclusion of a
large spectrum of hospital-based clinical data matched with
the administrative database, and (4) the use of previously
validated tools.
Limitations of this analysis are related to its pilot nature,
including a relatively small number of participants and a
substantial proportion of missing data. We were unable to
compare model performance by country because of a small
number of participating centers. We were also not able to
account for clustering by hospital because of the limited
number of outcomes per hospital. Furthermore, the study was
limited by the inability to match the patient data to the
administrative sample in all cases and to monitor that all
patients at each center were assessed with the NIHSS and the
mRS. In addition, the timeline of NIHSS score assessment in
acute stroke may be an important correlate of outcome, and
Table 3. Summary of C-statistics and Covariate Signiﬁcance
Outcome Outcomes (n) C-Statistic
Hosmer-Lemeshow
Statistic (P Value) NIHSS (P value) Age (P value) Sex (P value) CMI (P value)
Death7 30 0.897 7.6 (0.477) <0.0001 0.152 0.002 0.812
Death 49 0.880 5.5 (0.666) <0.0001 0.040 0.033 0.168
Death using mRS30 66 0.854 3.8 (0.873) <0.0001 0.003 0.003 0.639
Death using mRS90 88 0.814 5.6 (0.688) <0.0001 0.0001 0.042 0.110
mRS30 0 or 1 171 0.819 17.2 (0.029) <0.0001 0.0003 0.068 0.839
mRS90 0 or 1 190 0.826 15.2 (0.055) <0.0001 0.001 0.183 0.170
CMI indicates comorbidity index; Death, overall in-hospital mortality; death7, in-hospital mortality within 7 days; mRS30, modiﬁed Rankin Scale score at 30 days; mRS90, modiﬁed Rankin
Scale score at 90 days; NIHSS, National Institutes of Health Stroke Scale score.
Table 4. Marginal Proportion of Explained Variation Per
Covariate for Each Outcome
Outcome
NIHSS
(%)
Age
(%)
Sex
(%)
CMI
(%)
Model as a
Whole
In-hospital death by
day 7
11.3 1.2 1.4 0.7 16.6
In hospital death all 21.9 3.5 0.3 2.7 25.8
Death at 30 days 21.0 4.6 0.7 1.9 25.3
Death at 90 days 19.9 6.5 0.1 4.0 25.3
Good outcome* at
30 days
22.2 6.1 1.2 1.1 27.2
Good outcome* at
90 days
25.0 5.8 0.8 2.6 29.1
CMI indicates comorbidity index; NIHSS, National Institutes of Health Stroke Scale score.
*Good outcome equals a modiﬁed Rankin Scale score 0 or 1.
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in this study, the measure was obtained within 24 hours.
Although this is common in data sets using administrative
data, it limits generalizability. Nevertheless, the signiﬁcance of
NIHSS score for stroke outcome models is so strong that
there is a little doubt that our ﬁndings should be replicable in
research databases and other large samples.28
Another limitation is that the mRS score was not available
for all patients; therefore, selection bias cannot be excluded.
Given the available data, imputation of the missing data also
was not feasible; however, we found similar results in a large
research database (VISTA), indicating that 30- and 90-day
mRS scores were very strongly correlated and maybe used
interchangeably.14,17 Using the 30-day mRS score would
make stroke outcomes measurements easier to complete in
general stroke populations; small time windows are frequently
challenging in complex stroke populations, for which rehabil-
itation and other medical demands limit accessibility for
follow-up at speciﬁc time points.
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